Paris

• A Clinical Trial Assessing BT-001 Alone and in Combination With Pembrolizumab in Metastatic or Advanced Solid Tumors Ended
  2024-518529-14-00 7 2021-02-26 Metastatic/advanced soft tissue sarcoma (STS), Merkel cell carcinoma (
• Efficacy and Safety of Lenvatinib (E7080/MK-7902) Plus Pembrolizumab (MK-3475) Plus Chemotherapy in Participants With Advanced/Metastatic Ga … Ended
  2023-504834-23-00 11 2021-02-24 Advanced/Metastatic Gastroesophageal Adenocarcinoma
• Prospective Study to Characterize the Pharmacokinetics and Pharmacodynamics of Cufence (Trientine Dihydrochloride) in Wilson Disease Patient … Ended
  2024-516431-27-00 6 2021-02-23 Wilson’s Disease
• EFRAIM II _ Empirical steroids and/or antifungals treatment of immunocompromised patients with acute respiratory failure of uknown origin: a … Ended
  2024-514344-82-00 5 2021-02-18 patients with acute respiratory failure from undetermined etiology
• A study to evaluate the effects of ALIS based treatment in patients newly diagnosed with nontuberculous mycobacterial lung infection caused … Ended
  2023-505273-33-00 5 2021-02-15 "Adult Subjects with Newly Diagnosed Nontuberculous Mycobacterial (NTM
• A Phase 3, Open-label, Single Arm, Multicenter Study of Ravulizumab in Addition to Best Supportive Care in Pediatric Participants (from 1 mo … Ended
  2023-507850-33-00 5 2021-02-05 Hematopoietic stem cell transplant-associated thrombotic microangiopat
• A Clinical Trial to Test the Safety, Effect, and Activity of Rilzabrutinib (PRN1008) in Adult and Adolescent Patients with Persistent or Chr … Ended
  2023-509401-71-00 5 2021-02-05 Immune Thrombocytopenia (ITP)
• Study of efficacy and safety of LNP023 in primary IgA nephropathy patients. Ended
  2024-511067-29-00 5 2021-01-25 IgA Nephropathy
• Study Evaluating Cemiplimab Alone and Combined With RP1 in Treating Advanced Squamous Skin Cancer (CERPASS) Ended
  2024-512652-38-00 4 2021-01-25 Cutaneous Squamous Cell Carcinoma
• Mogamulizumab Every 4 Week dosing in Participants with R/R CTCL Ended
  2024-515921-27-00 4 2021-01-13 Mycosis fungoides/Sezary syndrome recurrent
• A Phase 3 Global, Multicenter, Double-Blind Randomized Study of Carboplatin-Paclitaxel With INCMGA00012 or Placebo in Participants With Inop … Ended
  2024-512331-72-00 5 2020-12-22 Squamous Carcinoma of the Anal Canal
• Placebo-controlled Study Comparing Niraparib Plus Pembrolizumab Versus Placebo Plus Pembrolizumab as Maintenance Therapy in Participants wit … Ended
  2023-508443-40-00 5 2020-12-18 Lung Cancer, Non-Small Cell
• A study of Gilteritinib combined with chemotherapy to treat Children, Adolescents and Young Adults with Relapsed or Refractory Acute Myeloid … Ended
  2024-512469-15-00 9 2020-12-08 FMS-like Tyrosine Kinase 3 (FLT3)/Internal Tandem Duplication (ITD) Po
• A 12-Month Study of Lasmiditan (LY573144) Treatment in Children Aged 6 to 17 With Migraine (PIONEER-PEDS2) Ended
  2023-506724-85-00 5 2020-11-19 Migraine
• A Study to Evaluate the Efficacy and Safety of Dupilumab in Adult Patients with Bullous Pemphigoid Ended
  2024-510745-34-00 10 2020-11-11 Bullous Pemphigoid
• A Study of Lasmiditan (LY573144) Treatment in Children Aged 6 to 17 With Migraine (PIONEER-PEDS1) Ended
  2023-506253-38-00 5 2020-11-09 Migraine
• A study to test Mirvetuximab Soravtansine (IMGN853) aganist doctor's choice of cancer medicines in women with advanced Epithelial Ovarian, P … Ended
  2024-516111-25-00 5 2020-11-09 Platinum-Resistant Advanced High-Grade Epithelial Ovarian, Primary Per
• Primary Progressive Multiple Sclerosis (PPMS) Study of Bruton's Tyrosine Kinase (BTK) Inhibitor tolebrutinib (SAR442168) (PERSEUS) Ended
  2024-514495-41-00 5 2020-11-04 Primary Progressive Multiple Sclerosis
• Efficacy of immunotherapy in combination with a drug in patients with advanced mucosal cancer of different locations that has progress. Ended
  2023-510320-71-00 4 2020-10-27 Squamous cell carcinoma of vulva/vagina
• A study of osilodrostat in children and adolescents with Cushing's disease Ended
  2024-516825-30-00 4 2020-09-21 Cushing's disease
• ISKPD-IFM2018-03-Multicenter Open label Phase 2 study of Isatuximab plus Pomalidomide and Dexamethasone with Carfilzomib in Relapsed or Refr … Ended
  2024-516670-29-00 4 2020-09-15 Multiple Myeloma
• Safety and Efficacy of Pembrolizumab in Combination With Investigational Agents or Pembrolizumab Alone in Participants with Melanoma (KEYMAK … Ended
  2023-506313-21-00 9 2020-08-03 PD-1 refractory melanoma
• Safety and Efficacy of Pembrolizumab in Combination With Investigational Agents or Pembrolizumab Alone in Participants With Stage III Melano … Ended
  2023-506314-51-00 9 2020-07-31 Stage IIIB or IIIC or IIID melanoma
• Safety and Efficacy of Pembrolizumab in Combination With Investigational Agents in Participants With Programmed Cell-death 1 (PD-1) Refracto … Ended
  2023-506312-41-00 9 2020-07-30 PD-1 refractory melanoma

Showing 2,137–2,160 of 2,286 trials